This page shows the latest Cardiovascular outcomes news and features for those working in and with pharma, biotech and healthcare.
primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke. ... In highlighting the lack of long-term evidence of the drug’s effect on cardiovascular outcomes, NICE also announced a
Overactivation of the mineralocorticoid receptor is believed to play a key role in kidney and cardiovascular damage, through inflammatory and fibrotic processes. ... The key secondary endpoint, which measures cardiovascular outcomes, found that the
Also, in post-hoc analysis of data from three large cardiovascular outcomes trials conducted by Novo Nordisk, which included 15, 820 patients with type 2 diabetes and a median follow-up
in adults with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalent and heterozygous familial hypercholesterolemia (HeFH). ... Another trial, dubbed ORION-4, is currently underway to determine if the reduction in LDL-C is coupled with an
outcomes study – not due to generate results until 2022 – before approval might be possible. ... Nexletol won’t be able to make a similar claim unless its cardiovascular outcomes trial comes out positive in 2022.
Swiss pharma also officially opens new London headquarters. Novartis announced yesterday that the UK will become the global centre a new clinical trial investigating inclisiran in improving cardiovascular outcomes. ... As a company working to improve and
More from news
Approximately 1 fully matching, plus 133 partially matching documents found.
Hyperkalaemia (elevated levels of potassium in the blood) and anaemia are both common complications of CKD, associated with poorer cardiovascular outcomes and an increased risk of hospitalisation and death. ... Joris Silon is Senior Vice President,
For individuals with diabetes, cardiovascular disease is the leading cause of morbidity and mortality. ... Against this backdrop, the ability to treat both type 2 diabetes by improving blood glucose control and substantially improve cardiovascular
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
In July 2012 he was appointed as Director for Reducing Premature Mortality on the NHS Commissioning Board (now NHS England), where he led the development of a cardiovascular outcomes strategy. ... These are vital attributes if the NHS is to navigate the
Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of results from the REDUCE-IT cardiovascular outcomes trial.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Disparities in cardiovascular health outcomes between different ethnic groups. Despite the progress that’s been made in treating heart disease, there is still a huge difference in mortality between white people ... Health outcomes are also related to
It also looks at other areas, such as cardiovascular and respiratory conditions, and explains how the NHS plans to change its approach in order to drive improvements in patient care and ... outcomes. Cardiovascular disease (CVD). Cardiovascular disease
Our client had recently conducted a series of clinical trials with its breakthrough cardiovascular product, resulting in outcomes data which had the potential to give it a more competitive edge and ... Communication strategies and marketing messages were
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...